There are two main risk factors for prostate cancer – your age and your family history. So, if you are a male and you have experienced any of the symptoms mentioned above you should talk to your GP and see if you are at risk.
As with many other diseases, the best protection against prostate cancer is to eat a nutritious diet and exercise regularly. So, whether you are at a higher risk of the disease or not, the best thing you can do is to eat well and move often!
If you are diagnosed with prostate cancer, it can be managed no initial treatment, active surveillance by your GP, or active treatment by a specialist. Active treatment may include radiotherapy, chemotherapy, hormone therapy or surgery; the most appropriate method is determined on an individual basis.
The good news is that the 1- and 5-year survival rate are 98% and 92% respectively!
Exercise Physiology is an excellent form of prehabilitation – before treatment – and rehabilitation – after treatment – for prostate cancer. Some excellent work done by Australian researchers has shown exercise can:
- Reverse muscle loss   
- Reverse bone mineral density loss   
- Improve energy levels 
- Is safe for prostate cancer with metastases 
If you have recently been diagnosed, or undergoing treatment for or recovering from prostate cancer, talk to one of our Exercise Physiologists about getting a tailored exercise program to be back to your best… 03 8370 3044
 Lim, K. B. (2017). Epidemiology of clinical benign prostatic hyperplasia. Asian Journal of Urology, 4(3), 148–151.
 , et al. Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data.
 Hart, N. H., Galvão, D. A., & Newton, R. U. (2017). Exercise medicine for advanced prostate cancer. Current opinion in supportive and palliative care, 11(3), 247-257.
 Galvao, D. A., Taaffe, D. R., Spry, N., Cormie, P., Joseph, D., Chambers, S. K., … & Newton, R. U. Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial. BJU International 120, 14.